Aktuellt
SENASTE
Redeye comments on Gasporox Q3 2023 report which came in below estimates. with net sales growing 4% y/y and missing our estimates by 23%. EBITDA was positive for the fifth straight quarter (not adjusting for capitalized R&D), showing a 7% ETBIDA margin. We expect volatility in Gasporox's results and we expect to make only minior changes due to the report.
LÄS MER
